retatrutide triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Triple hormone receptor agonist retatrutide

Mayo Clinic and Cleveland Clinic resources caution against non-FDA approved uses, citing lack of standardization and purity in non-pharmaceutical sources [mayoclinic.org], [my.clevelandclinic.org]

I had no complication whatsoever

In October 2022, the regulator issued a CRL, requesting additional information and analysis related to the infusion device and drug product across several areas of the New Drug Application (NDA)

Do not store it at room temperature, and do not freeze it unless you have a specific long-term storage protocol, as repeated freeze-thaw cycles can also degrade the compound

18 Overall, ALC was generally well tolerated, with predominantly mild GI and CNS events, and no evidence of excess serious AEs compared with controls